Ondansetron in the Prevention of Post Cardiotomy Delirium after Coronary Artery Bypass Grafting Surgery

Daniyal Ahmad Kamal; Muhammad Afsheen Iqbal; Sana Sarfraz; Atif Nawaz; Nasir Ali; Rehan Masroor; Fahad Ur Rehman; Ayesha Sana

doi:10.51253/pafmj.v73iSUPPL-3.10514

Authors

Daniyal Ahmad Kamal Department of Adult Cardiac Surgery, Armed Forces Institute of Cardiology/National Institute of Heart Diseases/ National University of Medical Sciences (NUMS) Rawalpindi, Pakistan
Muhammad Afsheen Iqbal Department of Adult Cardiac Surgery, Armed Forces Institute of Cardiology/National Institute of Heart Diseases/ National University of Medical Sciences (NUMS) Rawalpindi, Pakistan
Sana Sarfraz Department of Adult Cardiac Surgery, Armed Forces Institute of Cardiology/National Institute of Heart Diseases/ National University of Medical Sciences (NUMS) Rawalpindi, Pakistan
Atif Nawaz Department of Adult Cardiac Surgery, Armed Forces Institute of Cardiology/National Institute of Heart Diseases/ National University of Medical Sciences (NUMS) Rawalpindi, Pakistan
Nasir Ali Department of Adult Cardiac Surgery, Armed Forces Institute of Cardiology/National Institute of Heart Diseases/ National University of Medical Sciences (NUMS) Rawalpindi, Pakistan
Rehan Masroor Department of Adult Cardiac Surgery, Armed Forces Institute of Cardiology/National Institute of Heart Diseases/ National University of Medical Sciences (NUMS) Rawalpindi, Pakistan
Fahad Ur Rehman Department of Adult Cardiac Surgery, Armed Forces Institute of Cardiology/National Institute of Heart Diseases/ National University of Medical Sciences (NUMS) Rawalpindi, Pakistan
Ayesha Sana Department of Adult Cardiac Surgery, Armed Forces Institute of Cardiology/National Institute of Heart Diseases/ National University of Medical Sciences (NUMS) Rawalpindi, Pakistan

DOI:

https://doi.org/10.51253/pafmj.v73iSUPPL-3.10514

Keywords:

Coronary artery bypass grafting, Ondansetron, Post cardiotomy delirium, Serotonin

Abstract

Objective: To determine the efficacy of Ondansetron as a prophylctic agent in patients undergoing Coronary Artery Bypass
Grafting.

Study Design: Quasi-experimental study.

Place and Duration of study: Adult Cardiac Surgery Department, AFIC/NIHD Rawalpindi Pakistan, from Nov 2022 to Feb
2023.

Methodology: A total of 156 patients undergoing Coronary Artery Bypass Grafting Surgery irrespective of age and gender
were included in the study via nonprobability consecutive sampling. Patients who had a previous history of psychiatric
illness, and those in whom delirium could not be reliably tested were excluded from the study. The study population was
divided into two groups (group A and group B). Those in the group A received 8mg Ondansetron intravenously on zero, first and second post-operative day. Group B did not receive any intervention. Descriptive statistics were used to measure
percentages, frequencies and Mean±SD. Comparison between variables was made by Chi-square test for categorical variables and t-test for continuous variables. p<0.05 was considered statistically significant.

Results: Total 156 patients were included in the study and mean age of the patients was 59.47±10.98 years. A total of 3(14.3%) patients who had been given Ondansetron compared to 18(85.7%) patients who were not given Ondansetron developed delirium (p<0.001). Other factors significantly associated with post cardiotomy delirium were age (p<0.001), hypertension (p<0.001), and diabetes (p=0.03).

Conclusion: Our study revealed that Ondansetron can be used effectively to reduce the incidence of post cardiotomy delirium in patients of coronary artery bypass grafting.